<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03081052</url>
  </required_header>
  <id_info>
    <org_study_id>Pro00078035</org_study_id>
    <nct_id>NCT03081052</nct_id>
  </id_info>
  <brief_title>Inhaled Selective Pulmonary Vasodilators for Advanced Heart Failure Therapies and Lung Transplantation Outcomes</brief_title>
  <acronym>INSPIRE-FLO</acronym>
  <official_title>Inhaled Selective Pulmonary Vasodilators for Advanced Heart Failure Therapies and Lung Transplantation Outcomes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Duke University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Duke University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      1. to conduct a clinical investigation to determine if inhaled epoprostenol (Veletri速, iEPO)&#xD;
      and inhaled nitric oxide (iNO) will have similar impact on outcomes in adult patients&#xD;
      undergoing durable LVAD placement, heart transplantation, or lung transplantation 2. to&#xD;
      conduct a cost-capture analysis on the expense each drug incurs per patient.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In adult cardiothoracic surgical patients, iNO is used to treat precapillary pulmonary&#xD;
      hypertension (PH), right-sided heart failure (RHF), and ventilation-to-perfusion (V:Q)&#xD;
      mismatch. Adult patients who undergo durable LVAD implantation (e.g. Heartware速, Heartmate&#xD;
      2速, or Heartmate 3速), cardiac transplantation for HFrEF, or those that have endured lung&#xD;
      transplantation as a result of end-stage lung disease, compose the largest subpopulation&#xD;
      which receives iPVD therapy at Duke University Hospital. iEPO may display an equivalent&#xD;
      efficacy profile to iNO for pulmonary vasodilation and oxygenation and have a similar impact&#xD;
      on clinical outcomes.&#xD;
&#xD;
      424 informed and consented subjects undergoing LVAD placement or heart transplantation&#xD;
      (N=224) or lung transplantation (N=200) will be prospectively enrolled over a three-year&#xD;
      period (one-year for follow-up). Patients will be randomly assigned 1:1 according to&#xD;
      stratified randomization blocking either iNO or iEPO. Additional study procedures will&#xD;
      involve data collection, blood, and tissue sampling.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 4, 2017</start_date>
  <completion_date type="Anticipated">October 5, 2021</completion_date>
  <primary_completion_date type="Actual">October 5, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Other</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Grade 3 Primary Graft Dysfunction (PGD) for Lung Transplant subjects.</measure>
    <time_frame>Up to 72 hours</time_frame>
    <description>This is defined by the International Society of Heart and Lung Transplantation (ISHLT) as severe hypoxemia with a PaO2-to-FiO2 ratio &lt; 200 or the presence of venovenous extracorporeal membrane oxygenation (VV ECMO) at an time-point within the first 72 hours after lung transplantation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of moderate or severe RV failure for the LVAD implantation subjects.</measure>
    <time_frame>up to approximately 21 days after LVAD placement</time_frame>
    <description>This is defined by the Interagency Registry for Mechanically Assisted Circulatory Support (INTERMACS) scoring.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of severe RV failure for Heart Transplantation subjects.</measure>
    <time_frame>up to approximately 30 days after heart transplantation</time_frame>
    <description>This is defined by the incidence of an RVAD placement</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Duration of postoperative mechanical ventilation</measure>
    <time_frame>up to approximately 90 days</time_frame>
    <description>Length of time from intubation until patient is extubated</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Per patient cost</measure>
    <time_frame>up to approximately 30 days</time_frame>
    <description>Cost associated with the duration of PVD administration</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of ICU stay</measure>
    <time_frame>up to approximately 90 days</time_frame>
    <description>Length of time from ICU admission from surgery until ICU discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Length of hospital stay</measure>
    <time_frame>up to approximately 1 year</time_frame>
    <description>Length of time from surgery to hospital discharge</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Acute Kidney Injury</measure>
    <time_frame>up to approximately 14 days</time_frame>
    <description>defined by KDIGO-AKI criteria</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of in-hospital mortality</measure>
    <time_frame>up to approximately 1 year</time_frame>
    <description>Death that occurs during the hospital stay</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of postoperative mortality within 30 days</measure>
    <time_frame>up to approximately 30 days</time_frame>
    <description>From the day of surgery to 30 days (+/- 3 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of post-operative mortality within 90 days</measure>
    <time_frame>up to approximately 90 days</time_frame>
    <description>From the day of surgery to 90 days (+/- 5 days)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of post-operative mortality within 1 year</measure>
    <time_frame>up to approximately 1 year</time_frame>
    <description>From the day of surgery to 1 year (+/- 7 days)</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">424</enrollment>
  <condition>Heart Transplant Surgery</condition>
  <condition>Lung Transplant Surgery</condition>
  <arm_group>
    <arm_group_label>Lung transplant with iNO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Lung transplant with iEPO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Heart transplant &amp; LVAD implantation with iNO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Heart transplant &amp; LVAD implantation with iEPO</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iNO</intervention_name>
    <description>Subject will receive inhaled Nitric Oxide in this intervention</description>
    <arm_group_label>Heart transplant &amp; LVAD implantation with iNO</arm_group_label>
    <arm_group_label>Lung transplant with iNO</arm_group_label>
    <other_name>Inhaled Nitric Oxide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>iEPO</intervention_name>
    <description>Subject will receive inhaled Epoprostrenol in this intervention</description>
    <arm_group_label>Heart transplant &amp; LVAD implantation with iEPO</arm_group_label>
    <arm_group_label>Lung transplant with iEPO</arm_group_label>
    <other_name>Inhaled Epoprostrenol</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Heart transplantation&#xD;
&#xD;
          -  LVAD placement&#xD;
&#xD;
          -  Lung Transplantation&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Combined Organ Transplantation&#xD;
&#xD;
          -  Age &lt; 18 years old&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Known allergy to prostaglandin (rare)&#xD;
&#xD;
          -  Refusal of blood products due to personal or religious preference&#xD;
&#xD;
          -  Subject is enrolled in another study protocol, which does not allow randomization of&#xD;
             PVD therapy&#xD;
&#xD;
          -  Heart transplant or durable LVAD recipients with adult congenital heart disease (CHD)&#xD;
&#xD;
             o Caveat: Does NOT meet exclusion criteria if the scheduled heart transplant or LVAD&#xD;
             implantation is due to heart failure from a previous heart transplantation related to&#xD;
             CHD, performed more than 90 days previous to the date of trial enrollment&#xD;
&#xD;
          -  Heart transplant recipients diagnosed with Arrythmogenic Right Ventricular&#xD;
             Cardiomyopathy&#xD;
&#xD;
          -  Heart transplant recipients diagnosed with Acute Cardiac Allograft Rejection after a&#xD;
             previous heart transplantation.&#xD;
&#xD;
          -  Heart transplant or durable LVAD recipients with preoperative RVAD for right heart&#xD;
             failure&#xD;
&#xD;
          -  Patient is scheduled to undergo lung transplantation but has undergone heart&#xD;
             transplantation in the previous 90 days&#xD;
&#xD;
          -  Patient is scheduled to undergo durable LVAD implantation but has undergone heart&#xD;
             transplantation in the previous 90 days&#xD;
&#xD;
          -  Patient is scheduled to undergo heart transplantation but has undergone lung&#xD;
             transplantation in the previous 90 days&#xD;
&#xD;
          -  Patients with preoperative Venovenous ECMO as a bridge to lung transplantation&#xD;
&#xD;
          -  Heart transplant or durable LVAD recipients with preoperative RVAD for right heart&#xD;
             failure&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kamrouz Ghadimi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Duke Health</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Duke Health</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>March 8, 2017</study_first_submitted>
  <study_first_submitted_qc>March 14, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2017</study_first_posted>
  <last_update_submitted>November 5, 2020</last_update_submitted>
  <last_update_submitted_qc>November 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">November 6, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Heart and Lung transplantation surgery</keyword>
  <keyword>Pulmonary vasodilation therapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Nitric Oxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <pending_results>
    <submitted>October 5, 2021</submitted>
    <returned>November 2, 2021</returned>
  </pending_results>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

